Sudan Loganathan
Stock Analyst at Stephens & Co.
(4.15)
# 502
Out of 5,112 analysts
45
Total ratings
59.46%
Success rate
13.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Overweight | $95 | $75.50 | +25.83% | 1 | Dec 17, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $65 → $110 | $81.78 | +34.51% | 3 | Dec 11, 2025 | |
| CADL Candel Therapeutics | Reiterates: Overweight | $15 | $5.68 | +164.08% | 2 | Dec 8, 2025 | |
| PYXS Pyxis Oncology | Maintains: Overweight | $5 → $8 | $1.52 | +426.32% | 2 | Nov 24, 2025 | |
| IMNM Immunome | Maintains: Overweight | $25 → $33 | $20.04 | +64.67% | 3 | Nov 17, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $14 → $15 | $11.72 | +27.99% | 3 | Nov 10, 2025 | |
| DCTH Delcath Systems | Maintains: Overweight | $25 → $18 | $10.10 | +78.22% | 4 | Nov 5, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $35 | $25.25 | +38.61% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $2.03 | +195.57% | 3 | Sep 22, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $45 | $33.94 | +32.59% | 3 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $18.01 | +66.57% | 4 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $60 | $42.44 | +41.39% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $33 | $23.65 | +39.53% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $3.60 | +122.22% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $6.90 | +117.39% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.64 | +204.88% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $8.60 | +1,062.79% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.59 | +673.69% | 1 | May 14, 2024 |
Apogee Therapeutics
Dec 17, 2025
Initiates: Overweight
Price Target: $95
Current: $75.50
Upside: +25.83%
Kymera Therapeutics
Dec 11, 2025
Maintains: Overweight
Price Target: $65 → $110
Current: $81.78
Upside: +34.51%
Candel Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $15
Current: $5.68
Upside: +164.08%
Pyxis Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $1.52
Upside: +426.32%
Immunome
Nov 17, 2025
Maintains: Overweight
Price Target: $25 → $33
Current: $20.04
Upside: +64.67%
Arvinas
Nov 10, 2025
Maintains: Overweight
Price Target: $14 → $15
Current: $11.72
Upside: +27.99%
Delcath Systems
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $18
Current: $10.10
Upside: +78.22%
Centessa Pharmaceuticals
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $25.25
Upside: +38.61%
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.03
Upside: +195.57%
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $33.94
Upside: +32.59%
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $18.01
Upside: +66.57%
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $42.44
Upside: +41.39%
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $23.65
Upside: +39.53%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $3.60
Upside: +122.22%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $6.90
Upside: +117.39%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.64
Upside: +204.88%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $8.60
Upside: +1,062.79%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $2.59
Upside: +673.69%